Clinical Trials & Regulations: What Have We Learned From COVID?
Dr Christopher Corsico
Global Head of Development
Christopher D. Corsico, MD, MPH, is Global Head of Development at GSK, reporting to Chief Scientific Officer and President of R&D Hal Barron, responsible for development oversight of the GSK’s late stage portfolio though the end of the portfolio life cycle.
Prior to joining GSK, Chris worked at Boehringer Ingelheim for over 20 years in various roles including as Global Head of Medicine and Chief Medical Officer prior to joining GSK.
Chris was a Howard Hughes Medical scholar prior to receiving his medical degree from Cornell University College of Medicine. He subsequently received an MPH in chronic disease epidemiology from Yale University’s School of Public Health. Chris trained in Internal Medicine at Johns Hopkins, practicing medicine at the Johns Hopkins Medical Clinical and as an Assistant Professor of Internal Medicine at Dartmouth Medical School prior to joining industry.
Head of Decentralized Clinical Trials
Alison Holland is Head of Decentralized Clinical Trials at Medable, the leading SaaS platform for patient-centered clinical trials. Alison is chartered to design and expand the end-to-end capabilities needed to partially or fully virtualize clinical studies, building on the commitment to reduce clinical trial times by 50%.
Alison has over 20 years of experience in a variety of leadership roles, including Feasibility Head and Six Sigma Black Belt at Covance, and Business Head and global General Manager at Roche/Genentech in one of their therapeutic area business groups.
Having been engaged in over 300 studies across Biotechs, Pharma, and all geographies, Alison brings an incomparable level of insight and technical excellence on the matter of operational needs for sites and patients.
Prof Sir Martin Landray
Professor of Medicine and Epidemiology at Oxford University and co-chief investigator of the RECOVERY trial
Martin Landray is Professor of Medicine & Epidemiology at University of Oxford and Chief Executive of Protas, a not-for-profit company focused on the design and delivery of highly efficient randomized trials of treatments for major public health conditions. He has over 20 years’ experience of leading large, randomized trials of treatments for cardiovascular and kidney disease. Since March 2020, he has co-led the RECOVERY trial, enrolling over 47,000 patients with COVID-19 and publishing practice-changing results for 9 treatments (including the discovery that dexamethasone, tocilizumab, and neutralising monoclonal antibodies improve survival for selected patients with severe diseases). He leads the Good Clinical Trials Collaborative that is developing and promoting the implementation of better guidelines and regulations for randomized trials. He was a lead contributor to the G7 Clinical Trials Charter and the 100 Days Mission for Pandemic Preparedness. In June 2021, he was knighted for services to public health and science.
Prof Sir Menelas (Mene) Pangalos DSc PhD FRSB FMedSci HonFBPhS
EVP & President BioPharmaceuticals R&D
Mene is responsible for BioPharmaceuticals R&D from discovery through to late-stage development across CVRM, Respiratory & Immunology, Vaccines & Immune Therapies and Neuroscience. Since joining AstraZeneca in 2010, Mene has led the transformation of R&D leading to a greater than five-fold improvement in productivity.
Mene holds Honorary Doctorates from Glasgow University and Imperial College, London, is a Fellow of the Academy of Medical Sciences, the Royal Society of Biology and Clare Hall, University of Cambridge and is a Visiting Professor at The Wolfson Centre at Kings College. He co-chairs the UK Life Sciences Council Expert Group on Innovation, Clinical Research and Data and is a member of the Life Sciences Industrial Strategy Implementation Board. He is also on the Boards of The Francis Crick Institute, The Judge Business School, Cambridge University and Dizal Pharma, and is a member of the Life Sciences Vision Advisory Group. In 2019, Mene was awarded a knighthood from The Queen and the Prix Galien Medal, Greece. In 2021 Mene was awarded an Honorary Fellowship of the British Pharmacological Society. He has overseen the creation of AstraZeneca’s new Global R&D Centre in Cambridge and the companies COVID-19 efforts.
Dame June Raine
Medicines and Healthcare products Regulatory Authority (MHRA)
June Raine became Chief Executive of the MHRA in 2019, where she chairs the Executive Committee, the highest decision-making body in the Agency. Prior to this, she was Director of Vigilance and Risk Management of Medicines for 20 years. Recognised as one of the leading experts in the field of medicines safety, playing a central role in the Agency’s work. She led the MHRA while assessing the COVID vaccine data, and the MHRA was the first regulator to approve an mRNA vaccine for use in humans. June has extensive experience and knowledge of the Agency’s work, gained in a number of different licensing and post-licensing roles for medicines and medical devices. Her extensive experience includes chairing the European Pharmacovigilance Risk Assessment Committee (PRAC) on behalf of the European Medicines Agency from 2012 to 2018. June qualified in medicine at Oxford University, and undertook postgraduate research leading to an MSc in pharmacology.
Dr Myrto Lee
Managing Director & Partner
Myrto is a Managing Director and Partner at the Boston Consulting Group and a core member of the Health Care Practice based out of London. She focuses on R&D, regulatory, medical and market access. She has 22 years’ experience in Biopharma with 10 years in industry and 12 years in strategy consulting. Myrto started her career in Discovery Support in Pfizer at Sandwich and after her PhD worked with a cancer-vaccine biotech to support a phase III asset and bring a phase I radiopeptide into the clinic. She also spent 4 years at the MHRA as a senior pharmaceutical assessor working on a range of drug evaluations. Whilst in consulting Myrto has specialised in both strategy projects to support clients in developing robust strategies, enabling earlier access to medicines as well as large organisational transformations optimizing transaction and process efficiency and/or organisation effectiveness. Myrto is a UK registered pharmacist with a PhD in Advanced Drug Delivery Systems and a MBA from London Business School.